Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
We report on a patient with androgen ablation-refractory prostate adenocarcinoma who had an objective response for longer than 24 months using a combination of estramustine and lanreotide. At baseline from our combination therapy, his prostate-specific antigen level was 21.30 ng/mL and serum chromogranin A level was 816 ng/mL. The patient discontinued complete androgen deprivation therapy and underwent combination therapy with oral estramustine 420 mg/day plus lanreotide acetate 73.9 mg intramuscularly every 4 weeks. After 33 months of follow-up, the patient was alive without clinical disease progression, and his prostate-specific antigen and chromogranin A level was 0.10 and 12 ng/mL, respectively.
Cerulli
Costantino
C
Department of Urology, University La Sapienza, Rome, Italy.
Sciarra
Alessandro
A
Salvatori
Gianfilippo
G
Di Silverio
Franco
F
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D004961:Estramustine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013004:Somatostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D053379:Chromogranin A; D002864:Chromogranins; D010456:Peptides, Cyclic; C060347:lanreotide; D004961:Estramustine; D013004:Somatostatin; D017430:Prostate-Specific Antigen